Table 1 Correlations between the levels of CYP19A1 mRNA and histopathologic features in women with breast cancer
From: CYP19A1 gene expression in the peripheral blood of Brazilian women with breast cancer relapse
Variables Median age, 54 y (range, 34–82 y) | N (%) | CYP19A1 Expression | p value | |
|---|---|---|---|---|
Low (%) | High (%) | |||
Age | ||||
≤50 years | 60 (41.1) | 31 (21.2) | 29 (19.9) | 0.73 |
> 51 years | 86 (58.9) | 42 (28.8) | 44 (30.1) | |
Tobacco use | ||||
Yes | 55 (37.7) | 30 (20.5) | 25 (17.1) | 0.39 |
No | 91 (62.3) | 43 (29.5) | 48 (32.9) | |
Menopausal status | ||||
Premenopausal | 63 (43.2) | 31 (21.2) | 32 (21.9) | 0.86 |
Postmenopausal | 83 (56.8) | 42 (28.8) | 41 (28.1) | |
Tumor Grade | ||||
G1 | 14 (9.6) | 3 (2.1) | 11 (7.5) | 0.07 |
G2 | 107 (73.3) | 57 (39.0) | 50 (34.2) | |
G3 | 25 (17.1) | 13 (8.9) | 12 (8.2) | |
N Classification | ||||
N0-N1 | 127 (87.0) | 62 (42.5) | 65 (44.5) | 0.46 |
N2-N3 | 19 (13.0) | 11 (7.5) | 8 (5.5) | |
Tumor stage | ||||
I | 19 (13.0) | 7 (4.8) | 12 (8.2) | 0.40 |
II | 74 (50.7) | 40 (27.4) | 34 (23.3) | |
III | 53 (36.3) | 26 (17.8) | 27 (18.5) | |
Molecular subtype | ||||
Luminal A | 16 (11.0) | 6 (4.1) | 10 (6.8) | 0.06 |
Luminal B | 68 (45.2) | 36 (24.7) | 32 (21.9) | |
Her2 overexpression | 23 (15.8) | 12 (8.2) | 11 (7.5) | |
Triple-negative | 31 (21.2) | 19 (13.0) | 12 (8.2) | |
Hybrid Luminal | 8 (6.8) | 8 (5.5) | 0 (0.0) | |
Estrogen receptors | ||||
Positive Negative | 105 (71.9) 41 (28.1) | 52 (35.6) 21 (14.4) | 53 (36.3) 20 (13.7) | 0.85 |
Progesterone receptors | ||||
Positive Negative | 97 (66.4) 49 (33.6) | 49 (33.6) 24 (16.4) | 48 (32.9) 25 (17.1) | 0.86 |
HER2 | ||||
Positive Negative | 35 (24.0) 111 (76.0) | 14 (9.6) 59 (40.4) | 21 (14.4) 52 (35.6) | 0.17 |
Histological type | ||||
Ductal | 104 (71.2) | 50 (34.2) | 54 (37.0) | 0.73 |
Lobular | 8 (5.5) | 4 (2.7) | 4 (2.7) | |
Other | 34 (23.3) | 19 (13.0) | 15 (10.3) | |
Recurrence | ||||
Yes | 61(41.8) | 32 (21.9) | 29 (19.9) | 0.61 |
No | 85 (58.2) | 41(28.1) | 44 (30.1) | |